title: Differential adenosine uptake in mixed neuronal/glial or purified glial cultures of avian retinal cells: modulation by adenosine metabolism and the ERK cascade.
abstract: Adenosine is an important modulator of neuronal survival and differentiation in the CNS. Our previous work showed that nucleoside transporters (NTs) are present in cultures of chick retinal cells, but little is known about the mechanisms regulating adenosine transport in these cultures. Our aim in the present work was to study the participation of the adenosine metabolism as well as the ERK pathway on adenosine uptake in different types of retinal cultures (mixed and purified glial cultures). Kinetic analysis in both cultures revealed that the uptake reached equilibrium after 30 min and presented two components. Incubation of cultures with S-(p-nitrobenzyl)-6-thioinosine (NBTI) or dipyridamole, different inhibitors of equilibrative nucleoside transporters (ENTs), produced a significant and concentration-dependent uptake reduction in both cultures. However, while dipyridamole presented similar maximal inhibitory effects in both cultures (although in different concentrations), the inhibition by NBTI was smaller in glial cultures than in mixed cultures, suggesting the presence of different transporters. Moreover, pre-incubation of [(3)H]-adenosine with adenosine deaminase (ADA) or adenosine kinase (ADK) inhibition with iodotubercidin promoted significant uptake inhibition in both cultures, indicating that the uptake is predominantly for adenosine and not inosine, and that taken up adenosine is preferentially directed to the synthesis of adenine nucleotides. In both cultures, the MEK inhibitors PD98059 or UO126, but not the inactive analog U0124, induced a significant and concentration-dependent uptake decrease. We have not observed any change in adenosine metabolism induced by MEK inhibitors, suggesting that this pathway is mediating a direct effect on NTs. Our results show the expression of different NTs in retinal cells in culture and that the activity of these transporters can be regulated by the ERK pathway or metabolic enzymes such as ADK which are then potential targets for regulation of Ado levels in normal or pathological conditions.
authors.affiliation: Program of Neurosciences, Fluminense Federal University, Niterói, Brazil.
authors.forename: Alexandre
authors.initials: A
authors.lastname: dos Santos-Rodrigues
authors.forename: Jainne Martins
authors.initials: JM
authors.lastname: Ferreira
authors.forename: Roberto
authors.initials: R
authors.lastname: Paes-de-Carvalho
mesh_terms: D000241:Adenosine / Q000037:antagonists & inhibitors / Q000378:metabolism*; D000818:Animals; D002070:Butadienes / Q000494:pharmacology; D002478:Cells, Cultured; D002642:Chick Embryo; D033705:Equilibrative Nucleoside Transport Proteins / Q000378:metabolism*; D005419:Flavonoids / Q000494:pharmacology; D020930:MAP Kinase Kinase Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D020935:MAP Kinase Signaling System; D009095:Mullerian Ducts / Q000166:cytology; D009457:Neuroglia / Q000378:metabolism*; D009474:Neurons / Q000378:metabolism*; D009570:Nitriles / Q000494:pharmacology; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D012160:Retina / Q000378:metabolism*
chemical_list: D002070:Butadienes; D033705:Equilibrative Nucleoside Transport Proteins; D005419:Flavonoids; D009570:Nitriles; D047428:Protein Kinase Inhibitors; C113580:U 0126; D020930:MAP Kinase Kinase Kinases; D000241:Adenosine; C093973:2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one